Pharmaceutical Technology ePT Weekly:
Having trouble viewing this e-mail? Click here.
ePT by PharmTech logo
News
Product Spotlight
Industry Briefs
PharmTech,
the magazine

Advertisement

About Us

Subscribe to Pharmaceutical Technology

Whitepaper Library

Podcasts

Webcast: Overcoming Formulation Challenges of Parenteral Drugs
(On Demand)—Sponsored by Croda

Webcast: Best Practices for Achieving Product Quality in Sterile Manufacturing
November 6, 2012—Sponsored by Baxter

Webcast: API Development: Risk and Control of Genotoxic Impurities
November 8, 2012—Sponsored by Neuland

Webcast: Application of QWBA and Short-Lived Isotopes in the Drug Development Paradigm
November 29, 2012—Sponsored by MPI Research

MORE WEBCASTS

Events

PDA Pharmaceutical Quality System (ICH Q10) Conference
November 5, 2012–November 6, 2012
Tokyo, Japan

Preparation of FDA Submissions and Communicating with FDA
November 7, 2012–November 8, 2012
Dublin, Ireland

Lab Innovations
November 7, 2012–November 8, 2012
Birmingham, United Kingdom

Bio-Europe 2012
November 12, 2012–November 14, 2012
Hamberg, Germany

PDA FDA Pharmaceutical Supply Chain Conference
November 13, 2012–November 14, 2012
Bethesda, Maryland

More events


FindPharma Search

November 1, 2012 PharmTech.com PRINT SUBSCRIBE DIGITAL SUBSCRIBE



News

FDA Issues 483 to New England Compounding Center
New England Compounding Center has received a Form 483 from FDA for violating the Federal Food, Drug, and Cosmetic Act after the recent linked fungal meningitis outbreak.
Click Here to Read More

Third-Quarter 2012 Financial Reports Show Novartis and Merck Down
Pharmaceutical industry leaders Novartis and Merck—among others—released second-quarter 2012 results showing global sales down in third-quarter 2012, with growth in key pharmaceutical products helping to offset losses due to patent expirations.
Click Here to Read More

AET BioTech and BioXpress Therapeutics to Codevelop Adalimumab Biosimilar
AET BioTech and BioXpress Therapeutics have entered into an agreement to codevelop a biosimilar version of Abbott's tumor necrosis factor inhibitor monoclonal antibody adalimumab, currently marketed under the trade name Humira.
Click Here to Read More


Product Spotlight

Manufacturing process intelligent software helps improve process predictability

The latest version of Aegis’s Discoverant software can perform data aggregation, investigational analytics, and process modeling to improve process predictability and product quality. Discoverant 4.2 includes new features that were developed following input from Aegis customers, such as simplified user management and authentication with network-based group management, enhanced support for global collaboration across multiple time zones, new administrative reports, and greater control over query tools for easier model management. In addition, advanced analysis and data collection are made possible via the software’s InVision and PRIMR features.

Company Notes

Novartis has announced the construction of a new biotechnology facility in Singapore with an investment of over $500 million. The new facility will focus on drug-substance manufacturing based on cell-culture technology, and will be colocated with the pharmaceutical production site in Tuas, Singapore. Read More

Advertisement:
Brabender® Pharma USA, Inc. is an innovative company specializing in the manufacturing of twin-screw extruders for HME applications. The effort has been to concentrate on the finest quality equipment to produce small batch sizes up to production scale processes. The 12mm Mini-Compounder is ideally suited to this undertaking while other models offer options to achieve production capacity. For further details on the Mini-Compounder Click Here

The CDMO Patheon has agreed to acquire Banner Pharmacaps, a specialty pharmaceutical business dedicated to the research, development, and manufacturing of gelatin-based dosage forms. The acquisition will be structured as a purchase of all of the shares of the entities through which Banner conducts its operations, for $255 million, subject to working capital and other adjustments. The acquisition is subject to applicable regulatory approvals and other customary terms and conditions, and is expected to close by the end of 2012. Read More

Advertisement:
Free Technical Posters for Tablet Manufacturers
The latest edition to Natoli's extensive collection of free technical resources, the Technical Poster Series features 3 large-format posters packed with helpful tips, charts, terminology, and more. For a limited time, all 3 posters are available at no charge — shipping included — so order yours now! http://www.natoli.com/Posters-PT.html

Pfenex has awarded Althea Technologies a contract for the cGMP manufacturing of circumsporozoite protein from plasmodium falciparum, a malaria antigen. Althea Technologies will implement the cGMP-ready Pfenex Expression Technology-based production process that was developed at Pfenex over the past several months. Processes for several additional malaria antigens are currently being developed at Pfenex. Read More

A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers. Read More

Do you have news to report on facility expansions, contracts, service agreements, mergers, acquisitions, or personnel appointments? Send press releases to ptpress@advanstar.com


PharmTech, the magazine
Current Issue cover
Uniformity of Dosage Units Using Large Sample Sizes
by: Holte, M. Horvat
New European Pharmacopoeia chapter aims to resolve problems with applying the harmonized UDU test to large sample sizes.
Click Here to Read More

Coming soon: Don't miss our outsourcing early-stage development coverage in Pharm Tech's November issue.


Know Before You Go—2012 Conference Previews

Visit our Show & Exhibition Gateway 2012 to see which companies are exhibiting at upcoming industry conferences.

Find company backgrounds, new product releases, booth materials, and more.

PharmTech's online Gateway is your guide to the season's leading shows.

 

PharmTech Poll

Patent Cliff
2012 has been touted as a crucial year of the so-called patent cliff. Do you think the impact of patent expiries has been better or worse than expected?

Vote here
View the poll archive.
 
On Our Blog PharmTech Talk

>>Recent Posts

R&D
Third Quarter Revenues Wounded by Patent Expiries

Manufacturing, Regulation
FDA 483 Issued in the Calm before the Storm

North America News
Purdue Pharma Issues Grant to NASCSA to Combat Abuse and Diversion of Prescription Medications

>>Go to the Blog Homepage

| Subscribe | Send Feedback | Advertise With Us | Visit PharmTech.com |

Visit PharmTech.com Visit PharmTech.com About Us Subscribe Today! Start your RSS subscription today! Manufacturing Outsourcing Formulation Ingredients Testing Drug Delivery IT Packaging Regulation Visit PharmTech.com